How Pfizer Stock Can Rebound

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...
Fierce Biotech

Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called ...
Zacks Investment Research on MSN

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer PFE will report its third-quarter 2025 earnings on Nov. 4, before market open. The Zacks Consensus Estimate for sales ...

Jim Cramer on Pfizer: “The Drug Stocks Are Just in a World of Hurt, and This One Continues to Be There”

I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to ...

Where Will Pfizer Be in 5 Years?

Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.
Pharmaceutical Technology

Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing

Two of the world’s largest pharmaceutical companies, Pfizer (New York, US) and Roche (Basel, Switzerland), have unveiled more ...